P-BROMINDIONE is a potent, long-acting, inandione-derived, oral anticoagulant medication (Fig. 1). This report details our experience with the American synthesized product, Halinone. The identical chemical compound has been synthesized and evaluated clinically in Italy,1-4 where it is known under the chemical name "2(4 bromophenyl)-1,3-indandione."
Materials and Methods
Fifty-eight patients have received this medication for a combined total of over 10,000 patient days. In many instances treatment is continuing. The longest periods of continuous administration to any individual patients are slightly in excess of one and one-half years. All patients had or have thromboembolic disease as the indication for their short-term therapeutic or long-term prophylactic anticoagulant use.The laboratory monitoring of therapeutic response was carried out at appropriate intervals, using the prothrombin and proconvertin (P and P) method of Owren and Aas.5 The target for optimum anticoagulant effect was 20% P and P activity, with values ranging between